drugset / Trial / NCT05272150

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150

Phase 3 Completed 211 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.

Timeline

Start
2022-07-13
Primary completion
2025-05-30
Completion
2025-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody 100 mg Subcutaneous

Indications